Form 4: Kalaris Therapeutics Director Acquires Options Following Merger

Director Anthony P. Adamis reports acquisition of stock options in Kalaris Therapeutics following the merger with Kalaris Tx, Inc.

Summary

• Anthony P. Adamis, a director of Kalaris Therapeutics, Inc., filed a Form 4 on March 18, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of stock options as a result of the merger between Kalaris Therapeutics and Kalaris Tx, Inc.
• Adamis acquired 19,484 and 12,989 stock options with an exercise price of $0.55, exercisable beginning October 1, 2021, and expiring on July 25, 2032.
• These options were assumed in connection with the merger agreement dated November 7, 2024.
• The options vest over four years, with 25% vested by October 1, 2022, and the remainder vesting monthly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing reflecting a transaction related to a merger. There's no inherent positive or negative implication.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects following the merger.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in the holdings of a company director following a corporate event (merger).

Stakeholder Impact

• Shareholders are informed about changes in the holdings of company insiders.
• The filing provides transparency regarding the impact of the merger on executive compensation.

Key Dates